NYSE:DVA - New York Stock Exchange, Inc. - US23918K1088 - Common Stock - Currency: USD
DAVITA INC
NYSE:DVA (2/5/2025, 8:04:00 PM)
After market: 176.86 0 (0%)176.86
-0.49 (-0.28%)
The current stock price of DVA is 176.86 USD. In the past month the price increased by 16.72%. In the past year, price increased by 60.99%.
/PRNewswire/ -- DaVita Inc. (NYSE: DVA), announced today that it will hold its quarterly conference call to discuss fourth quarter results on Thursday,...
/PRNewswire/ -- DaVita, a comprehensive kidney care provider, is celebrating 25 years of clinical care delivery and leadership in healthcare innovation. Since...
/PRNewswire/ -- DaVita, a comprehensive kidney care provider, has activated its emergency response plan as devastating wildfires spread across Southern...
DaVita stock saw a welcome improvement to its Relative Strength (RS) Rating on Friday, with an upgrade from 64 to 72.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
CI | THE CIGNA GROUP | 10.73 | 81.58B | ||
CVS | CVS HEALTH CORP | 8.77 | 70.08B | ||
LH | LABCORP HOLDINGS INC | 17.34 | 20.91B | ||
DGX | QUEST DIAGNOSTICS INC | 18.28 | 18.40B | ||
BTSGU | BRIGHTSPRING HEALTH SERV - BTSG 6 3/4 02/01/27 | 177.13 | 14.50B | ||
FMS | FRESENIUS MEDICAL CARE-ADR | 14.8 | 14.42B | ||
HIMS | HIMS & HERS HEALTH INC | 95.91 | 9.22B | ||
CHE | CHEMED CORP | 24.57 | 8.43B | ||
CRVL | CORVEL CORP | 27.27 | 6.60B | ||
GH | GUARDANT HEALTH INC | N/A | 5.88B | ||
OPCH | OPTION CARE HEALTH INC | 26.32 | 5.33B | ||
RDNT | RADNET INC | 110.41 | 4.99B |
DaVita, Inc. engages in the provision of medical care services. The company is headquartered in Denver, Colorado and currently employs 70,000 full-time employees. The firm is a provider of kidney care services in the United States. Its United States dialysis and related lab services (U.S. dialysis) business treats patients with chronic kidney failure, end-stage kidney disease (ESKD). The Company’s robust platform delivers kidney care services and also includes established nephrology and payor relationships. The Company’s international operations provide dialysis and administrative services to a total of outpatient dialysis centers. The Company’s U.S. integrated kidney care (IKC) business provides integrated care and disease management services to patients in risk-based integrated care arrangements and to additional patients in other integrated care arrangements across the United States. The company also maintains a few other ancillary services and investments outside its U.S. dialysis, U.S. IKC, or international operations.
DAVITA INC
2000 16th St
Denver COLORADO 80202 US
CEO: Javier J. Rodriguez
Employees: 70000
Company Website: https://www.davita.com/
Investor Relations: https://investors.davita.com
Phone: 13105362668
The current stock price of DVA is 176.86 USD.
The exchange symbol of DAVITA INC is DVA and it is listed on the New York Stock Exchange, Inc. exchange.
DVA stock is listed on the New York Stock Exchange, Inc. exchange.
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for DVA, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of DVA.
DVA does not pay a dividend.
DVA will report earnings on 2025-02-13, after the market close.
The PE ratio for DVA is 19.92. This is based on the reported non-GAAP earnings per share of 8.88 and the current share price of 176.86 USD.
The outstanding short interest for DVA is 11.02% of its float.
ChartMill assigns a technical rating of 10 / 10 to DVA. When comparing the yearly performance of all stocks, DVA is one of the better performing stocks in the market, outperforming 91.09% of all stocks.
ChartMill assigns a fundamental rating of 6 / 10 to DVA. While DVA belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health.
Over the last trailing twelve months DVA reported a non-GAAP Earnings per Share(EPS) of 8.88. The EPS increased by 39.4% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 6.53% | ||
ROA | 4.73% | ||
ROE | 214.03% | ||
Debt/Equity | 23.95 |
ChartMill assigns a Buy % Consensus number of 53% to DVA. The Buy consensus is the average rating of analysts ratings from 16 analysts.
For the next year, analysts expect an EPS growth of 32.76% and a revenue growth 6.32% for DVA